• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Investing

Moderna stock jumps as pipeline progress and flu shot data lift sentiment

by July 2, 2026
written by July 2, 2026

Moderna Inc. (MRNA) shares rose 9.2% on Thursday, making the biotechnology company one of the top performers in the S&P 500.

Investors responded positively to new pipeline updates, encouraging influenza vaccine data, and favorable analyst commentary.

The stock extended its recent rally after climbing to a new annual high on Wednesday.

At one point, shares gained nearly 12% as investors welcomed the company’s latest Science Day presentation and progress across its mRNA development programs.

Investor sentiment also received a boost after an FDA advisory panel unanimously supported Moderna’s mRNA-1010/mFLUSIVA influenza vaccine for adults aged 50 to 64 and those 65 and older.

The recommendation comes ahead of a Prescription Drug User Fee Act (PDUFA) decision expected on Aug. 5, 2026, as well as planned global regulatory filings.

Science Day highlights broader pipeline expansion

During its recent Science Day presentation, Moderna outlined plans to expand its mRNA platform beyond infectious disease vaccines into oncology, autoimmune diseases and other therapeutic areas.

The company showcased programs targeting multiple myeloma, ovarian cancer and in vivo CAR-T therapies, while emphasizing increased use of artificial intelligence, machine learning, automation and robotics to accelerate research and development.

Plans to begin the in vivo CAR-T program mRNA-6007 in 2027 also contributed to investor optimism.

Chief Executive Officer Stéphane Bancel said the company’s strategy extends across multiple areas of development.

Working across three strategic horizons, we are applying our mRNA platform expertise to validate, scale and expand our modalities, with new modalities in the clinic, including T-cell engagers, and new modalities soon to be in the clinic, like in vivo CAR-T. At the same time, we are driving innovation by using data, AI and machine learning, and robotics to accelerate discovery and continuously improve how we execute for near-term growth while fuelling the next generation of mRNA medicines for patients around the world.

Stéphane Bancel
CEO, Moderna Therapeutics

Analysts see long-term opportunity

Analysts remained constructive on Moderna’s long-term prospects despite differing views on the pace of commercialization.

Jefferies maintained a Hold rating and a $45 price target, stating that while eventual approval of the influenza vaccine appears likely, meaningful flu-related revenue is not expected until 2027.

Piper Sandler took a more optimistic stance, raising its price target to $77 from $69 while reiterating an Overweight rating following the recent rally.

The positive analyst commentary added to growing optimism surrounding Moderna’s expanding pipeline beyond COVID-19 vaccines.

Financial position remains supported by cash reserves

Despite renewed enthusiasm surrounding its research programs, Moderna continues to operate at a loss as it invests heavily in product development.

The company generated approximately $389 million in quarterly revenue and about $1.94 billion in trailing 12-month revenue.

However, it reported a net loss of roughly $1.34 billion in the latest quarter and an EBITDA loss of approximately $1.28 billion. Free cash flow stood at negative $692 million.

Moderna has approximately $5.21 billion in cash and short-term investments, a current ratio of 2.4 and long-term debt of about $1.25 billion, providing financial flexibility as it continues investing in its pipeline.

CNBC’s Jim Cramer also expressed optimism about the company’s direction.

“For the first time in a long time, the company seems like it has something to get excited about”, Cramer said on Wednesday.

He added that Moderna’s “plethora of thoughtful, new products” is presenting a clear roadmap to profitability for the first time in a long while.

However, Cramer also urged patience, saying, “I recommend waiting for a pullback before you buy. Take your time. I think Moderna’s got a bright future though, but it’ll take years to get there.”

The post Moderna stock jumps as pipeline progress and flu shot data lift sentiment appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
Dow hits record high as weak jobs data eases Fed rate hike concerns
next post
Republican says Trump’s top election priority ‘dead’ in Senate as GOP fractures ahead of midterms

related articles

Michael Burry takes profits on Nvidia puts as...

November 20, 2026

Why Intel shares are falling over 5% on...

November 20, 2026

PayPal stock falls 4% as leadership shake-up tests...

November 20, 2026

Evening digest: Anthropic slides after record debut, Bitcoin...

November 20, 2026

Why Broadcom shares are down over 11% on...

November 20, 2026

Why CoreWeave and Nebius stocks are falling on...

November 20, 2026

SpaceX stock slips: why its 8.26% bond yield...

November 20, 2026

These 3 stocks are must-own for investors who...

November 20, 2026

Why is Tesla stock falling over 3% today?

November 20, 2026

Why AMD shares are tumbling over 6% on...

November 20, 2026
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • Akamai stock surges 23% on $12B Anthropic AI cloud deal: why it could double

    September 25, 2026
  • Meta stock jumps 4% after Muse Spark 1.3: why BofA still sees 32% upside

    September 8, 2026
  • AMD stock: why analysts are suddenly raising their price targets

    June 26, 2026
  • SpaceX stock opens at $150: analyst says it isn’t out of juice just yet

    June 12, 2026
  • Why is Meta stock up on Wednesday?

    September 16, 2026

Popular Posts

  • 1

    Why SpaceX stock is down around 3% on Tuesday

    September 15, 2026
  • 2

    Micron stock falls 4%, why this analyst sees 40% upside for the stock?

    September 28, 2026
  • 3

    Evening digest: US jobs cool, gold falls as Treasury yields rise

    October 2, 2026
  • 4

    Nike stock sinks after earnings as its comeback plan turns into more layoffs

    October 2, 2026
  • 5

    Dow rises 260 points as weak jobs data lifts US stocks

    October 2, 2026

Categories

  • Editor's Pick (711)
  • Investing (2,690)
  • Stock (90)

Latest Posts

  • Tesla stock hits crucial support as Xpeng teases ‘Model Y killer’ ahead of earnings

    July 19, 2026
  • AI rally lifts SK Hynix above Samsung in market capitalisation

    June 22, 2026
  • Republicans move to oust embattled Florida GOP lawmaker in bitter primary fight

    August 5, 2026

Recent Posts

  • AMD up 5% after strong Q3 beat as data center revenue nearly doubles

    November 4, 2026
  • Why Nvidia stock is in red today: growth case meets bearish warning

    October 23, 2026
  • 5 things to know before Wall Street opens on October 30

    October 30, 2026

Editor’s Pick

  • Applied Materials, KLA stocks gain as AI boom lifts chip equipment outlook

    June 11, 2026
  • SanDisk stock forms a highly bullish pattern: here’s why it may surge soon

    September 30, 2026
  • Apple stock: BofA recommends fixating on long-term opportunity

    November 3, 2026
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock